Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.

Androgen deprivation therapy (ADT) is the mainstay for the management of metastatic prostate cancer. Available pharmaceutical ADTs include gonadotropin-releasing hormone (GnRH) agonists and antagonists.